[{"orgOrder":0,"company":"Halix BV","sponsor":"University\u2019S Jenner Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Halix BV \/ University\u2019S Jenner Institute","highestDevelopmentStatusID":"10","companyTruncated":"Halix BV \/ University\u2019S Jenner Institute"},{"orgOrder":0,"company":"Halix BV","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Vaccine","year":"2020","type":"Collaboration","leadProduct":"ChAdOx1 nCoV-19","moa":"Immunostimulant","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Halix BV \/ AstraZeneca","highestDevelopmentStatusID":"10","companyTruncated":"Halix BV \/ AstraZeneca"},{"orgOrder":0,"company":"Halix BV","sponsor":"NovalGen","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Antibody","year":"2021","type":"Partnership","leadProduct":"NVG-111","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Halix BV","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Halix BV \/ NovalGen","highestDevelopmentStatusID":"6","companyTruncated":"Halix BV \/ NovalGen"}]

Find Clinical Drug Pipeline Developments & Deals by Halix BV

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Vietnam Medi Pharm
                          Not Confirmed
                          Vietnam Medi Pharm
                          Not Confirmed

                          Details : HALIX will provide manufacturing and clinical supply of NovalGen's therapies as part of this partnership. HALIX has supported NovalGen with the successful completion of GMP manufacture of NVG-111 from drug substance up to drug product and final release.

                          Product Name : NVG-111

                          Product Type : Antibody

                          Upfront Cash : Undisclosed

                          February 22, 2021

                          Lead Product(s) : NVG-111

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : NovalGen

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          02

                          Vietnam Medi Pharm
                          Not Confirmed
                          Vietnam Medi Pharm
                          Not Confirmed

                          Details : Under the agreement, HALIX will provide commercial manufacturing of drug substance at its state-of-the-art cGMP facility at the Leiden Bio Science Park in the Netherlands. To meet the increased demand, HALIX expands with two additional viral vector produ...

                          Product Name : AZD1222

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          August 12, 2020

                          Lead Product(s) : ChAdOx1 nCoV-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : AstraZeneca

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Vietnam Medi Pharm
                          Not Confirmed
                          Vietnam Medi Pharm
                          Not Confirmed

                          Details : Under the collaboration, Halix will utilise its brand new state-of-the-art GMP facilities with capacity up to 1,000 L SUB scale, supporting the manufacture of ChAdOx1 nCoV-19 clinical trial material.

                          Product Name : AZD1222

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          April 15, 2020

                          Lead Product(s) : ChAdOx1 nCoV-19

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : University’S Jenner Institute

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank